When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device and is mainly used to make the site work as you expect it to. The information does not directly identify you but can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to learn more and change our default settings. However, blocking some types of cookies may impact your experience of the site. You can find more information, including a detailed cookie explanation, on our Cookie Policy.
Quibim partners with Merck KGaA, Darmstadt, Germany to develop next wave of imaging-based diagnostics for precision medicine
25 January, 2024 – Quibim, the global company transforming imaging data into actionable predictions of cancer progression and treatment response, is today announcing that it is collaborating with leading science and technology company Merck KGaA, Darmstadt, Germany to develop the next generation of precision medicine technology targeting a wide range of cancers.
The two companies are exploring how to harness the potential of biomarkers and radiomics to predict a cancer patient’s response to immunotherapy and anticipate cancer patient outcomes. Quibim will contribute its years of expertise in utilizing AI to develop predictive and prognostic models able to enhance patient stratification and contextualize potential benefit of novel therapies at a patient-, dose- and/or treatment-level. Merck KGaA, Darmstadt, Germany seeks to integrate these models as it continues to advance data-driven decision-making within its global drug development and commercialization strategies.
Enhancing the efficiency of clinical development for cancer medicine is a critical and global challenge, particularly in light of the rapidly increasing number of cancer patients in need of personalized treatment. According to the Global Cancer Observatory, there will be an estimated 30 million new cases of cancer worldwide each year by 2040, up from 19 million in 20201. To face this, Quibim and Merck KGaA, Darmstadt, Germany’s research will be laser-focused on finding technological solutions able to reduce costs and timelines for pharmaceutical development while also improving success rates.
Angel Alberich-Bayarri, Co-Founder and CEO of Quibim, commented on the partnership: “Our partnership with Merck KGaA, Darmstadt, Germany is poised to be a game-changer in the field of oncology by applying our cutting-edge imaging-based methodologies. We’re on a mission to optimize each phase of clinical development and chart a course towards a new era in precision medicine, where data-driven insights enhance patient care and deliver more efficient, effective and tailored treatments.”
About Quibim
Quibim is a company designing pioneering tools that unlock imaging data to improve patient outcomes. With offices in New York (United States), Cambridge (UK), Valencia, Madrid, and Barcelona (Spain), the company was born from the ambition of turning imaging into a catalyst for precision health. Quibim leads the forefront of imaging biomarkers research in life sciences, pioneering the development of advanced algorithms that transform imaging data into actionable predictions in oncology, immunology and neurology. The company leverages the capabilities of MRI, CT, and PET imaging to create regulatory-cleared Medical Devices that are seamlessly integrated into the workflows of healthcare providers worldwide. More than 150+ sites are using Quibim products globally.
Contact information
1. https://gco.iarc.fr/tomorrow/en/dataviz/isotype